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ABSTRACT
Molecular analysis of BRCA1 (MIM# 604370) and BRCA2 (MIM #600185) genes is 
essential for familial breast and ovarian cancer prevention and treatment. An efficient, 
rapid, cost-effective accurate strategy for the detection of pathogenic variants is 
crucial. Mutations detection of BRCA1/2 genes includes screening for single nucleotide 
variants (SNVs), small insertions or deletions (indels), and Copy Number Variations 
(CNVs). Sanger sequencing is unable to identify CNVs and therefore Multiplex Ligation 
Probe amplification (MLPA) or Multiplex Amplicon Quantification (MAQ) is used 
to complete the BRCA1/2 genes analysis. The rapid evolution of Next Generation 
Sequencing (NGS) technologies allows the search for point mutations and CNVs 
with a single platform and workflow. In this study we test the possibilities of NGS 
technology to simultaneously detect point mutations and CNVs in BRCA1/2 genes, 
using the OncomineTM BRCA Research Assay on Personal Genome Machine (PGM) 
Platform with Ion Reporter Software for sequencing data analysis (Thermo Fisher 
Scientific). Comparison between the NGS-CNVs, MLPA and MAQ results shows how the 
NGS approach is the most complete and fast method for the simultaneous detection 
of all BRCA mutations, avoiding the usual time consuming multistep approach in the 
routine diagnostic testing of hereditary breast and ovarian cancers.
INTRODUCTION
Most cases of breast and ovarian cancers are sporadic. 
However, up to 20% of patients are likely to harbor a 
dominant susceptibility allele, with highly increased risk 
of malignancy above the general population. Many genes, 
when mutated, increase risk of breast cancer development 
[1]. Some of them work either as cell cycle controllers in 
response to DNA damage or in DNA Double-Strand Breaks 
Repair by homologous recombination; however, the most 
part of them have low or moderate penetrance, and are 
rarely involved. Notable exceptions are the BRCA1 and 
the BRCA2 genes, whose mutations have high penetrance 
and are found in nearly 40% of cancer patients [2–4]. 
Cumulative cancer risks at age 70 years were breast cancer 
risk of 57% for BRCA1 and 49% for BRCA2 mutation 
carriers; and ovarian cancer risk of 40% for BRCA1 and 
18% for BRCA2 mutation carriers. [5, 6]. BRCA1 and 
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BRCA2 pathogenic variants include point mutation, small 
insertion/deletion and large genomic rearrangements 
(LGRs). Copy Number Variation (CNV) is a structural 
variation where a DNA segment of 1Kb to several Mb in 
length is present in variable copies compared to a reference 
genome sequence [7]. Although these structural variants do 
not always display phenotypic consequences, sometimes 
they may influence gene expression and be associated with 
specific phenotypes [8]. LGRs are responsible for 4-28% 
of all inherited BRCA mutations [9–11]. Pathogenic CNVs 
in BRCA1 and BRCA2 genes range respectively from 0 
to 27% and 0% to 8% [12–14] The higher frequency of 
LGRs in BRCA1 compared to BRCA2 gene is caused by 
higher density of ALU sequences [15], which mediate the 
formation of LGRs [16, 17]. LGRs in BRCA1 and BRCA2 
vary across populations and ethnicities [18–20], with a 
frequency up to 12% in Italy [21]. Many approaches have 
been used for detecting BRCA LGRs, such as comparative 
genomic hybridization (CGH), array comparative genomic 
hybridization (aCGH), real Time PCR (qPCR) and 
fluorescent in situ Hybridization (FISH) [22]. In 2006, a 
test for identifying large rearrangements in these genes 
(BRAC-Analysis Rearrangement Testing) was released 
from Myriad. Nowadays, the Multiplex ligation-dependent 
probe amplification (MLPA, MRC-Holland, Amsterdam, 
the Netherlands) is the primary method for detecting LGRs 
in BRCA1/2 with the Multiplex Amplicon Quantification 
(MAQ) (Multiplicon, Niel, Belgium), as an alternative way 
[23–25]. Both approaches are consistent, but they always 
need the confirmation with other techniques, because of 
the possibility of false positive results [21]. For many 
years, BRCA gene analysis on peripheral blood has been 
using Sanger sequencing and MLPA. The Next Generation 
Sequencing (NGS) had definitively replaced the Sanger 
method since it is extremely fast and cost-effective as a 
routine analysis. The rapid evolution of NGS allows to add 
LGRs to point mutation screening in a single workflow, 
further reducing the time for the complete analysis of 
BRCA1/2 genes. However, NGS-CNV detection has not 
been validated for clinical diagnostics yet [26, 27]. In 
this work we evaluated the use of the PGM Ion Torrent 
platform for the simultaneous identification of CNVs, 
single nucleotide variants (SNVs) and indels (single or 
multiple insertion/deletion), using a single integrated 
workflow. Data obtained from the NGS-CNV detection 
have been compared with those achieved by MLPA and 
MAQ. The results show how the NGS workflow on the Ion 
PGM platform can be used for the identification of any type 
of pathogenic variants of the BRCA1/2 genes. This analysis 
pipeline could be used in diagnostic and predictive tests for 
hereditary breast and ovary cancer, as this approach proved 
to be fast, reliable and accurate both in identifying SNVs 
and indels, and in the simultaneous analysis of CNVs.
RESULTS
Mutational data
DNA was analyzed for point mutations and CNVs 
by a single workflow. PGM sequencing produced an 
Table 1: Indel and SNV variants detected by Oncomine™ BRCA Panel
Gene Transcript Locus Coding Protein Function dbSNP Clinical Significance
Enigma 
Classification
Sample 
ID
BRCA1 NM_007294.3 chr17:41267797 c.81-1G>C p.? unknown rs80358018 Pathogenic C 5 P17
BRCA1 NM_007294.3 chr17:41243725 c.3823A>G p.Ile1275Val missense rs80357280 Uncertain 
significance
C 3 P05
BRCA1 NM_007294.3 chr17:41245667 c.1881C>G p.Val627Val synonymous rs80356838 Uncertain 
significance
C 3 P07
BRCA1 NM_007294.3 chr17:41244526 c.3018_3021delTTCA p.His1006Glnfs*17 frameshiftDeletion rs80357749 Pathogenic C 5 P08
BRCA1 NM_007294.3 chr17:41243788 c.3756_3759delGTCT p.Ser1253Argfs*10 frameshiftDeletion rs80357868 Pathogenic C 5 P11
BRCA1 NM_007294.3 chr17:41244262 c.3285delA p.Lys1095Asnfs*14 frameshiftDeletion rs397509051 Pathogenic C 5 P16
BRCA1 NM_007294.3 chr17:41228628 c.4361T>C p.Val1454Ala missense rs587782606 Uncertain 
significance
C 3 P13
BRCA1 NM_007294.3 chr17:41209079 c.5266dupC p.Gln1756Profs*74 frameshiftInsertion rs80357906 Pathogenic C 5 P04
BRCA1 NM_007294.3 chr17:41215920 c.5123C>A p.Ala1708Glu missense rs28897696 Pathogenic C 5 P10
BRCA2 NM_000059.3 chr13:32905069 c.700delT p.Ser234Profs*7 frameshiftDeletion rs80359630 Pathogenic C 5 P12
BRCA2 NM_000059.3 chr13:32907102 c.1487C>T p.Ser496Phe missense rs397507269 Uncertain 
significance
C 3 P01
BRCA2 NM_000059.3 chr13:32906458 c.846_847delCA p.Ile283Trpfs*11 frameshiftDeletion rs886040776 Pathogenic C 5 P15
BRCA2 NM_000059.3 chr17:32913381 c.4889C>G p.Ser1630Ter nonsense rs80358711 Pathogenic C 5 P18
BRCA2 NM_000059.3 chr13:32915053 c.6566dupA p.Asn2189Lysfs*8 frameshiftInsertion rs397507373 Pathogenic C 5 P02
BRCA2 NM_000059.3 chr13:32914953 c.6468_6469delTC p.Gln2157Ilefs*18 frameshiftDeletion rs80359596 Pathogenic C 5 P09
BRCA2 NM_000059.3 chr13:32944593 c.8386C>T p.Pro2796Ser missense rs146120136 Uncertain 
significance
 C 3 P14
Abbreviations: dbSNP: Single Nucleotide Polymorphisms database (www.ncbi.nlm.nih.gov/SNP); ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) 
http://www.enigmaconsortium.org: C5: Class 5 – (there is significant evidence to suggest that this variant is a dominant high-risk pathogenic variant, C3: Class 3 (there is insufficient 
evidence, molecular or otherwise, to be classified as a high-risk pathogenic variant, thus requires further investigation.
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average of 244,000 reads per patients, the mean read 
length being 110 bp. The average read depth per sample 
was 1220X, with a mean percentage of reads on target of 
95%. The mean percentage of regions of interest (ROI) 
covered at least by 100X was 100%, and uniformity of 
base coverage by 99.5%. Details for each samples of 
the sequencing metrics are reported in Supplementary 
Table 1. Among 81 women with breast cancer who 
pursued genetic testing, 19 allelic variants were identified 
(detection rate 23%), 14 pathogenic (P) variants (74%, 
14/19) including one splicing site mutation, one nonsense, 
one missense, 9 frameshifts, and three CNVs, all reported 
in the BRCA Exchange database (http://brcaexchange.
org/); five mutations are classified as variants of uncertain 
significance (VUS) (Table 1). All samples analyzed for 
CNVs by the VCIB (Variability Correction Informatics 
Baseline) algorithm showed a confidence score > 20, 
indicating a high quality call of CNVs (Table 2). All 
results obtained by NGS-CNV detection were confirmed 
by MLPA (Supplementary Figure 1). Sixty-nine samples 
out 81 were negative for big indels (Supplementary 
Figure 2), while three samples (about 4%) showed an 
exon 20 deletion, exons 21 to 22 deletion and exon 24 
deletion on the BRCA1 gene respectively, with relative 
peak ratio (RPR) values about 0.5 (normal range 0.7-1.3). 
The identified CNVs were confirmed by the MAQ test, 
the dosage quotient (DQ) values were 0,57 for exon 20 
deletion, 0.53-0.51 for exon 21-22 deletion and 0.53 for 
exon 24 deletion (normal range 0.75-1.3). Comparison 
between the results obtained through NGS-CNVs, MLPA 
and MAQ technology are summarized in Figure 1.
Perfomance of the single workflow for SNVs, 
indels and CNVs detection
The single Oncomine workflow used for BRCA1/2 
genetic test allowed us to detect simultaneous all type of 
variants on BRCA1/2 genes. Using this single integrated 
workflow on single platform, turnaround time of mutation 
testing was reduced. This approach allows to a single 
technician to perform the complete BRCA1/2 analysis in 
a series of 16 patients (collected in two weeks) making 
the diagnostic reports available for the clinician in 25 
working days following blood sampling, compared to 45 
days required with separate workflows for point mutations 
and CNVs. To assess the sensitivity and specificity in the 
detection of SNVs and indels, we compared the variant 
calling results from four DNA samples, pre-tested by 
Ion AmpliSeq Panel to detect germline variants, with 
the results obtained by Oncomine® BRCA1/2 Panel. The 
comparison was restricted to the ROI regions (BRCA1/2 
coding regions +/- 20 bp) covered by both panels’ designs. 
All variants previously called by Ion AmpliSeq panel were 
successfully confirmed using the Oncomine® BRCA1/2 
Panel, except for a false call in a homolymeric region of 
the BRCA2 gene (Supplementary Table 2).
Finally, to check the performance of NGS-CNVs 
detection, all samples analyzed with VCIB algorithm 
Table 2: Large rearrangements detected by NGS-CNV analysis in P03, P06 and P19 patients
Sample ID Locus Type CNV Subtype Call Genes CytoBand Length
Variant 
Class
Copy 
Number
CNV 
Confidence
P03
chr13:32890490 CNV REF exon 2-27 BRCA2 13q13.1(32890490-
32972932)x2
82.442kb  2 100
chr17:41197601 CNV BigDel exon 24 BRCA1 17q21.31(41197601-
41197870)x1
269kb exon 
deletion
1 30.53
chr17:41199538 CNV REF exon 2-23 BRCA1 17q21.31(41199538-
41276123)x2
76.585kb  2 100
P06
chr13:32890490 CNV REF exon 2-27 BRCA2 13q13.1(32890490-
32972932)x2
82.442kb  2 100
chr17:41197601 CNV REF exon 21-24 BRCA1 17q21.31(41197601-
41203234)x2
5.633kb  2 69.58
chr17:41208956 CNV BigDel exon 20 BRCA1 17q21.31(41208956-
41209231)x1
275kb exon 
deletion
1 78.56
chr17:41215248 CNV REF exon 2-19 BRCA1 17q21.31(41215248-
41276123)x2
60.875kb  2 100
P19
chr13:32890490 CNV REF exon 2-27 BRCA2 13q13.1(32890490-
32972932)x2
82.442kb  2 100
chr17:41197601 CNV REF exon 23-24 BRCA1 17q21.31(41197601-
41199764)x2
2.163kb  2 34.61
chr17:41201009 CNV BigDel exon 21-22 BRCA1 17q21.31(41201009-
41203234)x1
2.225kb exon 
deletion
1 100
chr17:41208956 CNV REF exon 2-20 BRCA1 17q21.31(41208956-
41276123)x2
67.167kb  2 100
Abbreviations: REF: read count matches with the reference baseline; BigDel: deletion of at least one exon; CNV confidence: The confidence score is the probability that the 
number of copies of the region of interest is different from 2, which is the normal value. A high confidence score indicates a higher probability that the identified variant is a true 
positive. A confidence score of 10 or 20 or higher indicates a high quality copy number variant's call.
Oncotarget33651www.oncotarget.com
of Ion Reporter Server System 5.6, were re-analyzed 
by MLPA analysis. In addition, the CNVs identified in 
tree samples on BRCA1 gene were analyzed by MAQ 
technique. CNV NGS data compared to MLPA and/
or MAQ revealed a 100% of sensitivity, specificity and 
accuracy (Supplementary Table 3).
DISCUSSION
The mutational spectrum of BRCA1/2 is large, 
including different classes of variants, such as SNVs, 
indels and LGRs. Fast test results are crucial when patients 
with breast/ovarian cancer and their unaffected family 
members must be addressed to the appropriate therapy and 
surveillance respectively. Sanger sequencing and MLPA 
so far represented the gold standard for the complete 
BRCA1/2 testing. However the possibility of analyzing all 
types of mutations through a single workflow offered by 
the NGS is appealing. Therefore several research groups 
have tested different NGS platforms for CNVs detection 
by implementing and validating customized workflow 
[21, 28-30].
In this study, we evaluated the possibility of 
using the PGM platform for the simultaneous analysis 
of indels, SNVs, and CNVs in BRCA1/2 genes, by the 
OncomineTM BRCA Research assay and Ion Reporter 
5.6 Software, which includes two different algorithms 
for different classes of variant calling. The OncomineTM 
BRCA Panel replaced the previously used Ion 
AmpliseqTM Panel on the PGM platform for BRCA1/2 
diagnostic testing. Another study showed a better 
performance of the OncomineTM BRCA Research assay 
compared with the Ion AmpliseqTM BRCA Panel in terms 
of ability to identify deletions at homopolymer sites, on 
target mapped reads, reduction of low-quality mapped 
reads and false-negative results. In the same study, using 
the Oncomine Panel a large deletion was identified, 
subsequently confirmed by MLPA [31]. The NGS-CNV 
analysis requires a complete validation of the "baseline", 
which is crucial to obtain accurate and reliable results 
for clinical applications. For this purpose, we used the 
VCIB algorithm to build the baseline and set up basic 
parameters. To validate NGS accuracy on CNV detection 
we selected forty-eight samples, without big indels on 
BRCA1/2 genes when tested by MLPA. Using a single 
workflow, we identified on BRCA1/2 genes three large 
rearrangements and 16 point mutations. The clinical 
features of BRCA1/2 carriers mutations are summarized 
Figure 1: Large rearrangements identified in P06, P19, P03 patients by NGS-CNV workflow respectively in exon 20, 
21-22 and 24 of BRCA1 gene compared with MLPA and MAQ results. (A) CNV-NGS rappresentative images, the red box 
indicates the BRCA1 exon 20 deletion, exon 21-22 deletion and exon 24 deletion, sequencing reads of BRCA1 (red) and BRCA2 (blue) were 
normalized with sample ID (sid) tag sequencing reads (green). (B) MLPA results: the probes relative to exon 20, 21-22 and 24 show a RPR 
value about 0.5 compared to normal range value of reference probes (normal range : 0.7 – 1.3 red and blue line), blue rhombus represents 
the 95% confidence interval over the reference samples for each probe. The .collected data were analyzed using Coffalyser.NET Software 
(MRC Holland). (C) MAQ results show the 0.57 DQ value relative to BRCA1 exon 20, 0.53 and 0.51 for exon 21-22 and 0.53 for exon 24. 
The gray profiles are obtain on reference DNA sample, (normal range 0.75 – 1.3).
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in Supplementary Tables 4 and 5. Seventy-eight out of 
eighty-one samples were normal for BRCA1/2 copy 
number variations (Figure 1, Supplementary Figure 
2) Results obtained by the NGS-CNV algorithm were 
confirmed with MLPA and pathogenic CNVs were also 
confirmed with MAQ, with 100% concordance. For what 
concerns reduced costs, they have been mainly obtained 
by using a single protocol and reagents for the complete 
analysis of BRCA1/2 genes. Moreover, the baseline 
implemented in the bioinformatics pipeline for the NGS-
CNVs analysis does not need to insert additional control 
samples for each analysis, further reducing cost effective 
for a single sample; for the library preparations a very 
low input concentration of DNA is required compared 
with MLPA analysis. Using this workflow also the time 
of analysis has been drastically reduced obtaining two 
analyzes in a single solution and avoiding to introduce 
further errors and limiting contamination problems. We 
can conclude that NGS-CNV could be used as valid and 
safe alternative to MLPA assay; the NGS approach for 
CNV analysis could represent an effective procedure 
to apply to all patients in routine BRCA1/2 molecular 
screening. Comprehensive and accurate analysis of 
BRCA1/2 genes is essential for individual and family 
genetic counseling in hereditary breast and ovarian 
cancers [32], as well as for establishing drug therapy 
with poly(ADP-ribose) (PARP) polymerases inhibitors 
in patients with high-grade serous ovarian cancer 
[33, 34]. Therefore, reducing the timing of mutation 
screening becomes fundamental in clinical oncology. 
We confirm in this study the accuracy and precision of 
NGS workflow for simultaneous detection of CNVs and 
point mutations of BRCA1/2 genes, suggesting the use 
of this technological advancement in the diagnostic-
therapeutic and care assessment of hereditary breast and 
ovarian cancer.
MATERIALS AND METHODS
Patients
A consecutive series of 81 Italian women with 
breast/ovarian cancer and/or positive family history have 
been enrolled in this study between July and December 
2017, after receiving genetic counseling at U.O.C Medical 
Genetics and Cellular Diagnostic of Department of 
Clinical and Molecular Medicine, “Sapienza” University 
of Rome. The eligibility of patients for BRCA1/2 testing 
was evaluated using BRCAPRO 5.0 model (University of 
Texas http://www.stat.duke.edu/~gp/brcapro.html) and/or 
for the presence of specific anamnestic criteria based on 
Italian guidelines from the Operational program 2016-
2018, Lazio Region decree: DCA 52/201 that identify the 
high-risk woman for being BRCA mutation carriers. All 
tested individuals signed an informed consent for genetic 
research. Investigation has been conducted in accordance 
with the 1964 Helsinki Declaration.
Mutational analysis
A single NGS platform, the Personal Genome 
Machine (PGM) (Thermo Fisher Scientific, Carlsbad, 
CA, USA), has been used for the simultaneous detection 
of point mutations and CNVs in BRCA1/2 genes. For this 
purpose OncomineTM BRCA Research Assay (Thermo 
Fisher Scientific), containing 265 primers pairs in two 
pools was performed according to the manufacturer’s 
protocol on PGM machine. Genomic DNA was extracted 
from whole EDTA blood using a commercially available 
kit (Invitrogen, Pure link Genomic DNA by Thermo 
Fisher Scientific) and quantified using Qubit ds DNA 
HS Assay Kit on Qubit 3.0 Fluorimeter (Invitrogen). The 
detected variants are classified based on the criteria of the 
ENIGMA (Evidence-based Network for the Interpretation 
of Germline Mutant Alleles) consortium (https://
enigmaconsortium.org) and described as recommended by 
Human Genome Variation Society (https://www.hgvs.org/) 
using as RefSeq: NM_007294.2 and NM_000059.3. Point 
mutations classified as P and VUS have been confirmed 
by Sanger sequencing, using the BigDye Terminator v3.1 
sequencing kit and the ABI PRISM 3130 Genetic Analyzer 
(Life Technologies). To confirm the results obtained 
by NGS-CNV workflow, all the samples analyzed by 
Ion Reporter Software 5.6 were tested with Multiplex 
Ligation-dependent Probe Amplification (MLPA) and/or 
Multiplex Amplicon Quantification (MAQ).
BRCA1/2 MLPA analysis was performed using 
P002-D1 and P045-C1 SALSA MLPA kits (MRC-
Holland, Amsterdam, the Netherlands) in according to 
manufacturer’s instructions. DNA samples were diluted 
to final 50ng/ul concentration, and four normal controls 
were included in each MLPA analysis. The fragments 
analysis was performed using 3130 Genetic Analyzer 
(Applied Biosystem) with size standard GeneScan 
TM 500 Liz. Variations in peaks areas were analyzed 
using Coffalyser.Net (MRC-Holland, Amsterdam, the 
Netherlands).
The MAQ (v1.0 kit, Multiplicon, Niel, Belgium) is 
a straightforward method for the detection and analysis 
of copy number variations (CNVs). It consists of the 
simultaneous PCR amplification of fluorescently labeled 
target amplicons of BRCA1 and BRCA2 exons followed 
by fragments analysis. The comparison of normalized 
peak area between test and reference sample results in a 
dosage quotient (DQ) indicating the copy of LGR. MAQ 
kit includes two Master reaction mix (Plex A and Plex B) 
containing primer for 55 BRCA1/2 amplicons target (TA) 
and 17 control amplicons (CA). The fragment analysis was 
run on 3130 Genetic Analyzer (Applied Biosystem) and 
for analysis results was used the MAQ-S v2.0 software 
(Multiplicon, Niel Belgium).
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Library preparation
The OncomineTM Panel used for library preparation, 
cover 100% of the coding sequences of BRCA1 and 
BRCA2, including all splice sites with an average of 64 
bp extensions from the intron junctions. In according to 
the manufacturer’s instructions, 10ng of DNA isolated 
from whole blood per target amplification reaction (20ng 
total) were used to generate the sequencing libraries 
with two premixed pools of 265 primers. Briefly, 
after target amplification in 10ul reactions, pool 1 and 
pool 2 amplification reactions are combined into new 
wells in the plate. After partial digestion of primers, 
ligation of barcode adapters, and amplicon purification, 
barcoded libraries are quantified and diluted to 100pM 
concentration, and combined before template preparation. 
Clonal amplification of the libraries was carried out by 
emulsion PCR using Ion PGM™ Hi-Q™ View OT2 Kit 
on Ion OneTouch 2 Instrument and the Ion OneTouch 
ES (Enrichment System) (Thermo Fisher Scientific) to 
produce high-quality Ion Sphere™ particles for use in 
combination with the Ion PGM™ Hi-Q™ View Sequencing 
Kit. Finally, the prepared libraries were then sequenced 
on an Ion PGM™ System platform, using Ion 316™ Chip 
v2 BC. Sequencing data analysis was performed using 
Torrent Suite version 5.0.5 and Ion Reporter version 5.6 
(Thermo Fisher Scientific).
SNVs, indel and CNVs detections
The Torrent Suite Software running in Torrent 
Server (DEL T7500 OS Ubuntu 10.04 LTS) has been 
used to process raw data acquired by PGM. The generated 
raw sequence data, in FASTQ format, have been aligned 
to the hg19 human reference genome using the Torrent 
Mapping Alignment Program. The base calls, in SFF 
and FASTQ file formats were used for downstream 
analysis, containing per-base quality scores. Following 
the analysis, the annotation of single nucleotide variants, 
indels and CNVs was performed using the Ion Reporter 
Server System v.5.6. The analysis of the CNVs required 
the setting of the integrated software for germline CNVs 
analysis. In the proprietary algorithm used to call copy 
number changes in individual exons, named VCIB 
(Variability Correction Informatics Baseline), has been 
inserted a baseline consisting of samples normal for 
BRCA1/2 CNVs. The selection of samples for the baseline 
was made between those previously analyzed for all type 
of BRCA1/2 mutations, using Oncomine BRCA Panel for 
point mutations analysis on PGM and the MLPA for CNVs 
detection on Sanger sequencer. Among these, we selected 
48 samples without big indels in the BRCA1/2 genes, with 
a value of mapped reads > 100,000 and a MAPD (Median 
of the Absolute values of all Pairwise Differences) <0.5. 
The MAPD is a metric that evaluates whether panel 
data can be used for CNV analysis. The Copy Number 
estimates are made by VCIB algorithm counting reads for 
each amplicon, making adjustments to account for certain 
types of variability like those derived from imbalance 
pool. The Sequence data were evaluated using Integrative 
Genomics Viewer (IGV) (http://software.broadinstitute.
org/software/igv/).
Abbreviations
BigDel: deletion of at least one exon; CNV: copy 
number variation; FISH: fluorescent in situ hybridization; 
INDEL: single or multiple insertion/deletion; LGR: large 
genomic rearrangement; MAPD: median of the Absolute 
values of all Pairwise Differences; MAQ: multiplex 
amplicon quantification; MLPA: multiplex ligation 
probe amplification; NGS: next generation sequencing; 
P:pathogenic; PARP: poly(ADP-ribose) polymerases; 
PGM: personal genome machine; REF: read count 
matches with the reference baseline; ROI: regions of 
interest; RPR: relative peak ratio; SNV: single nucleotide 
variant; VCIB: variability correction informatics baseline; 
VUS: variant of uncertain significance.
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